Literature DB >> 31054641

International incidence of psychotic disorders, 2002-17: a systematic review and meta-analysis.

Hannah E Jongsma1, Caitlin Turner2, James B Kirkbride3, Peter B Jones4.   

Abstract

BACKGROUND: The last comprehensive systematic review of the incidence of psychotic disorders was published in 2004. New epidemiological data from different settings now permit a broader understanding of global variation. We examined the variation in psychosis by demographic characteristics and study method.
METHODS: For this systematic review and meta-analysis, we searched PubMed, Embase, Web of Science, PsycINFO, and bibliographies, and directly contacted first authors. We sought to obtain citations of original research published between Jan 1, 2002, and Dec 31, 2017, on incidence of non-organic adult-onset psychotic disorder. We included papers that were published or in grey literature and had no language restrictions. Data were extracted from published reports, where possible, by sex, age, and ethnic group. Quality of yield was assessed. Data were assessed using univariable random-effects meta-analysis and meta-regression. We registered our systematic review on PROSPERO, number CRD42018086800.
FINDINGS: From 56 721 records identified, 177 met inclusion criteria. The pooled incidence of all psychotic disorders was 26·6 per 100 000 person-years (95% CI 22·0-31·7). Heterogeneity was high (I2≥98·5%). Men were at higher risk of all psychotic disorders (incidence rate ratio 1·44 [1·27-1·62]) and non-affective disorders (1·60 [1·44-1·77]) than women, but not affective psychotic disorders (0·87 [0·75-1·00]). Ethnic minorities were also at excess risk of all psychotic disorders (1·75 [1·53-2·00]), including non-affective disorders (1·71 [1·40-2·09]). Meta-regression revealed that population registers reported higher rates of non-affective disorders (9·64 [2·72-31·82]), schizophrenia (2·51 [1·24-5·21]), and bipolar disorder (4·53 [2·41-8·51]) than first contact study designs.
INTERPRETATION: We found marked variation in incidence of psychotic disorders by personal characteristics and place. Some geographical variation could be partially explained by differences in case ascertainment methods. FUNDING: None.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Mesh:

Year:  2019        PMID: 31054641      PMCID: PMC6693560          DOI: 10.1016/S2468-2667(19)30056-8

Source DB:  PubMed          Journal:  Lancet Public Health


Introduction

Psychotic disorders are associated with substantial premature mortality,1, 2 morbidity, and a large social and financial burden. Yet, research into their distribution and determinants has only in the past decade extended beyond North America and northern Europe6, 7, 8 to southern Europe,9, 10, 11, 12 South America, Africa,14, 15 and other low-income and middle-income countries (LMICs).15, 16 These new data might provide new clues to the determinants of the heterogeneity in the incidence of psychotic disorders between and within different populations reported in previous studies,17, 18 aiding both service planning and our understanding of cause; both are crucial for planning effective public mental health responses. The most recent comprehensive systematic review and meta-analysis was published in 2004 and was restricted to schizophrenia. Further meta-analyses have limitations in terms of single country coverage, search scope, yield and assessment of heterogeneity, specific population group coverage20, 21 or coverage of a particular risk factor,22, 23, 24, 25, 26 or were also restricted to schizophrenia. Together, these reviews showed that estimates of the incidence of psychotic disorders vary across replicable demographic, geographical, and social characteristics. Men and young people appear to have an excess risk,27, 28 as do migrants and their descendants.20, 29, 30 Settings at higher latitude and more urban settings also yield higher incidences.26, 31 Socioeconomic deprivation, inequality, and instability are also associated with increased incidence.14, 32, 33, 34 Earlier meta-analyses17, 18, 35 found no evidence of variation in incidence by study quality or other methodological features. Research suggests36, 37 that higher incidences are derived from population registers (which cover all health-care contacts within an entire health system) than from first-contact studies (which rely on individuals making contact with appropriate services). These comparisons notwithstanding, methodological heterogeneity as an explanation for variation in incidences has not been investigated widely. We sought to synthesise the accumulating research on the incidence of adult-onset psychotic disorders (including affective psychotic disorders) and investigate whether sociodemographic factors or methodological heterogeneity accounted for any observed variation. Consistent with available evidence, we hypothesised that incidences would be higher in men, younger people, and those from ethnic minority groups, and in register-based studies. Evidence before this study We searched PubMed and Web of Science (appendix p 4) for international systematic reviews and meta-analyses of the incidence of non-organic psychotic disorders in the general population, published since the last major review of the evidence (published in 2004). Our search yielded 156 results, of which 14 were meta-analyses. However, these commonly examined a single risk factor for psychotic disorders, such as migrant status, or synthesised evidence of incidence in a particular segment of the population, such as the elderly. Only one meta-analysis met all inclusion criteria and summarised incidence in the general population, but this study provided no assessment of heterogeneity. Added value of this study To the best of our knowledge, this study is the first comprehensive systematic review and meta-analysis of the incidence of non-organic adult-onset psychotic disorders done in 16 years and provides an update on the epidemiological landscape. For the first time, we also formally assessed if incidence of psychotic disorders varies by study type. Incidence varied substantially between settings: a 10 times variation in incidence was observed across diagnostic categories. We also found that studies with routine registers reported higher incidences of disorder than studies with a service-based design. Implications of all the available evidence Variance in the incidence of psychotic disorders worldwide arises from both replicable social, demographic, and environmental determinants, and from methodological heterogeneity. Although most studies continue to be done in a handful of countries, future studies across more diverse settings will benefit from standardised methods to facilitate comparable estimates of incidence across the globe.

Methods

Search strategy and selection criteria

This systematic review and meta-analysis followed PRISMA guidelines (appendix pp 2–3), including preregistering our protocol with PROSPERO (CRD42018086800) before extraction of data. Our method is based on a previous systematic review. We systematically searched PubMed, PsycINFO, Web of Science, and Embase, adapting a previously used search strategy based on Cochrane Systematic Reviewing guidelines. This strategy used terms covering psychotic disorders and incidence and was adapted for each database (appendix p 4). We searched bibliographies of included citations and directly contacted authors to request data, where appropriate. We restricted our review to studies published between Jan 1, 2002, and Dec 31, 2017. We had no restriction on language of publication, study design, or publication status, although grey literature was only identified via published conference proceedings, author correspondence, and bibliographical searches. Citations were considered eligible if they contained incidence data or data from which incidence could be derived (numerator and denominator); included patients (aged 18–64 years) diagnosed with a first episode of any psychotic disorder; were published between Jan 1, 2002, and Dec 31, 2017, and were published in the scientific or grey literature, online, or in print. Two authors (HEJ, CT) carried out searches and screened the titles found to assess whether they met eligibility criteria, with definite or possible titles forwarded to duplicate independent abstract review and, if appropriate, full text review. Uncertainties about inclusion were resolved in agreement with two senior authors with experience in epidemiological research and systematic reviewing (JBK, PBJ). The study protocol is available online.

Data analysis

Two authors (HEJ, CT) extracted data. Study-level data about study characteristics, rate-level data about incidences, and meta-level data on time period, study quality, study design, and diagnostic criteria (see below) were included. The primary outcome was incidence per 100 000 person-years of all psychotic disorders (International Classification of Disease tenth edition [ICD-10] = equivalent, F20–33), non-affective disorders (F20–29), schizophrenia (F20), affective disorders (F30–33), bipolar disorder with psychosis (F30–31), psychotic depression (F32–33), or substance-induced psychosis (F1X.5). Included studies used a range of diagnostic classifications, including ICD-8, ICD-9, and ICD–10, and the Diagnostic and Statistical Manual of Mental disorders (DSM) versions 3-R and 4, and we assumed sufficient commonalities to pool citations (appendix p 5). Where possible, we extracted summary-level incidence data on the exposures age, sex, ethnicity, and migrant status. Meta-level data on study design, study quality, and time period were recorded. Study design was divided into first-contact studies (which count the number of people attending the relevant service, and include first presentation, first diagnosis, first GP record, first admission, and first treatment), cohort studies, case-register studies (with a dedicated national patient register), and studies with a general population register covering an entire health system. Time period was defined as the median year of the case ascertainment period. Where incidences were not directly reported, we derived them from ancillary information wherever possible. Where citations reported overlapping data from the same study or population, we used set criteria to establish inclusion (appendix p 4). The full spreadsheet containing all study-level, rate-level, and meta-level data is available online. Two independent raters (HEJ, JBK or CT) assessed study quality according to seven previously published criteria: designation of a defined catchment area, accurate reporting and reliable source of denominator data, population-based case finding, standardised research diagnosis used, masking (of the clinician) to demographic variables, inclusion criteria stated, and inclusion of a leakage study (appendix p 4). We first did a narrative synthesis of the yield. Based on previous meta-analyses,17, 18 we anticipated high levels of heterogeneity and therefore specified use of random-effects meta-analysis and meta-regression a priori to quantify this heterogeneity. When five or more incidences could be pooled, we did random-effects meta-analyses using the DerSimonian and Laird method, grouping citations by study design. We transformed incidence rates to their natural logarithm and entered into meta-analyses with corresponding standard errors (SE)s. If no SE could be derived, we retained studies for narrative synthesis only. For assessments of differences in incidence by sex and ethnicity, we estimated incidence rate ratios (IRRs), transformed them to their natural logarithm, and entered them into meta-analyses with their corresponding SEs. We assessed statistical heterogeneity using the Q test and quantified using the I2 statistic, which identifies the proportion of the observed variance that reflects real differences in effect size. We examined evidence of small study effects (including publication bias) by visual inspection of funnel plots and formal testing using Egger's test for which at least 10 estimates were available. We did random-effects meta-regression to explore whether heterogeneity was associated with study quality, study design, or time period. We did meta-analyses in Stata (version 13) using the metan and admetan commands. We did meta-regressions using the metareg package, and we did funnel plots and Egger's tests using the metafunnel and metabias packages. We chose to display pooled estimates to prevent ad-hoc summaries of data but considering the high expected heterogeneity, the emphasis in interpretation of results is on the variation in incidences.

Role of the funding source

There was no funding source for this study.

Results

We retrieved 56 721 records of which 177 met inclusion criteria (figure 1; table); 93 (53%) of 177 had sufficient data available for meta-analysis and meta-regression. Most studies (140 [79%] of 177) were done in Europe, with 14 (8%) done in North America. Few studies were done in Asia (11 [6%]), the Middle East (seven [4%]), Australia, Latin or South America (four [2%] each), or Africa (two [1%]). Two citations covered more than one continent.15, 55 Citations examining psychosis in young people (26 [15%]), comorbid groups (12 [7%]), the army (seven [4%]), a prison population (one [<1%]), and post-partum psychosis (five [3%]) are synthesised in the appendix (pp 8–12) because they are not representative of the general population. The most frequently studied diagnostic outcome was schizophrenia (86 [49%]), followed by all non-affective disorders (66 [37%]) and all psychotic disorders (59 [33%]). Any affective psychotic disorder as an outcome was less frequently studied (32 [18%]), although we identified 40 (22%) citations of bipolar disorder with psychosis and 15 (8%) citations of psychotic depression. Six (3%) citations examined substance-induced psychosis.
Figure 1

PRISMA flowchart

*Citations derived from Kirkbride and colleagues, which cover England only from 2002–09.

Table

Study characteristics of included citations

CountryPeriodTypeDiagnostic confirmationDiagnostic classificationDiagnostic outcomesNumber of cases
Tsuchiya et al 200261*Denmark1980–97First admission..ICD-8, ICD-10SchzUnknown
Hanoeman et al 200262*Surinam1992–93First admissionMedical recordsDSM-3-RSchz, schzp73
Selten et al 200263Netherlands1970–92Case registerNoneICD-8, ICD-9SchzUnknown
Baldwin et al 200264Ireland1995–2000First contactSCID or medical recordsDSM-4FEP69
Scully et al 200265*Ireland1995–2000First contactSCID or medical records..FEP69
Boydell et al 200366*England1965–97Case registerCase notes plus OPCRITCombinationSchz623; 385
Smith et al 200367Canada1907–13First admissionClinical recordsDSM-4Schz, schzp, bpd831
Singh et al 200368England2000First contactInterview, questionnaire, case notes..FEP295
Selten et al 200369Netherlands1990–96Case registerDischarge summaryICD-9Bpd, pd14 749
Cantor-Graae et al 200370Denmark1970–98Population registerNoneICD-8, ICD-10Schz10 244
Baldwin et al 200371Ireland1995–2002First contactSCID or clinical recordsDSM-4FEP, non-aff, schiz, aff, bp, pd, other146
Proctor et al 200472England1998–2001Case registerChart diagnosisICD-10FEP, non-aff, schz, aff, bp, pd, sip, other227
Sipos et al 200473Sweden1989–2001First admissionNoneICD-9, ICD-10Non-aff, schz1950
Chien et al 200474Taiwan1997–2001First contactNoneICD-9Schz419
Boydell et al 200475*England1988–97CombinationCase records using OCCPIRDCSchz222
Veen et al 200476Netherlands1997–99First contactDiagnostic meetingDSM-4FEP, non-aff, aff, oth181
Singh et al 200477England1992–94First contactInterview, SCAN or SANS and OCCPI or OPCRITICD-10FEP, non-aff, schz, aff, sip, oth168
Sailas et al 200578§Finland1984–94CohortNoneOtherFEP71
Harris et al 200579*Australia..First presentationConsensusDSM-4, ICD-10FEP, schz, aff94
Sundquist et al 200580Sweden1997–99Population registerNoneICD-9, ICD-10FEP, pd6163
Nager et al 200581Sweden1986–97CohortNoneICD-9, ICD-10FEP339
Laursen et al 200582Denmark1952–87Population registerNoneICD-8, ICD-10Schz, schza, bp18 147
Selten et al 200583Surinam2002–03First contactCASH interview, panel discussionDSM-4FEP64
Nixon et al 200584England1881–1994CombinationCase notesRDCSchz41
Qin et al 200585Denmark1950–87Population registerNoneICD-8, ICD-10Non-aff, schz795
Allardyce et al 200586Scotland1989–93First admissionCase recordICD-9FEP5838
Cantor-Graae et al 200587Sweden1999–2001First contactClinical, case records, additional dataDSM-4FEP, non-aff150
Baldwin et al 200543Ireland1995–2003First contactSCID or clinical diagnosisDSM-4FEP, non-aff, schz, aff, bpd, pd, oth194
Kennedy et al 2005a88England1965–99CombinationCase notes plus OPCRITDSM-4Bpd246
Kennedy et al 2005b89*England1965–99CombinationCase notes plus OPCRITDSM-4, ICD-10Bpd246; 235
Lloyd et al 200590England1997–99First contactInterview (SCAN, SANS, modified PPHS), consensus diagnosisICD-10Bpd75
Leão et al 20068Sweden1992–99Population registerNoneICD-9, ICD-10Non-affUnknown
Bray et al 200691Canada1975–85First contactNoneICD-10Schz1962
Payne et al 200692Canada1993–95First admissionClinical records..Non-aff146
Drukker et al 200693Netherlands1993–2002Case registerNoneDSM-4Schz98
Turner et al 200694**England1999–2002First admissionCase notes, ratified by psychiatristICD-10Non-aff, schz62
Mahmmood et al 200695England2005–05First contactUnknown..FEP303
Westman et al 200696Sweden1997–98Population registerNoneICD-9, ICD-10FEP10 800
Munk-Olsen et al 200697Denmark1955–90Population registerNoneICD-8, ICD-10Non-aff, schz166
Smith et al 200644Canada1902–13First admissionClinical recordsDSM-4Schz, schza, schp, oth807
Amminger et al 200698Australia1997–2000First treatmentYouth assessment team, random sample SCID or RPMIPDSM-4FEP1019
Veling et al 20067Netherlands1997–2005First contactDiagnostic meetingDSM-4Non-aff181
Morgan et al 200699England1997–99First contactInterview (SCAN), case notes, consensus meetingICD-10FEP, schz592
Fearon et al 2006100*England1997–99First contactInterview (PSE SCAN), case notes (IGC SCAN)ICD-10FEP, schz, bpd, pd, oth568
Gould et al 2006101England1997–99First presentationWHO screening for psychosis plus OPCRITICD-10FEP111
Kirkbride et al 20066England1997–99First contactSCAN, consensus panelDSM-4FEP, non-aff, schz, aff, sip568
Zipursky et al 2006102England1997–99First contactSCAN, consensus panelDSM-4FEP, schzUnknown
Li et al 2007103Sweden1984–2004Population registerNoneICD-9, ICD-10FEP40 228
Schimmelmann et al 2007104*Australia1998–2000First admissionSCID and clinical diagnosis comparisonDSM-4FEP636
Laursen et al 2007105Denmark1995–87Population registerNoneICD9, ICD-10Schz, bpd17 787
Ajdacic-Gross et al 2007106Switzerland1977–2005Case registerNoneICD-8, ICD-9FEP, schz7230
Andersen et al 2007107Norway1887–2005First admissionCase recordsICD-10Schz, aff64
Harlow et al 2007108Sweden1987–2001CohortNoneICD-8, ICD-9Non-aff, schz, schza, bpd2134
Juvonen et al 2007109Finland1950–59Population registerCase notes (2 experts)DSM-4Schz807
Cantor-Graae et al 2007a110Denmark1986–2006Population registerNoneICD-8, ICD-10Schz4609
Cantor-Graae et al 2007b111Denmark1970–2001Population registerNoneICD-8, ICD-10Schz10 779
Leão et al 2007112*Sweden1995–98Population registerNoneICD-9, ICD-10Non-aff, affUnknown
Kikbride et al 2007a113England1997–99First contactSCAN, consensus panelICD-10FEP, non-aff, aff295
Menezes et al 200713Brazil2002–2004First contactSCID-I or case notesDSM-4FEP, non-aff, aff367
Kirkbride et al 2007b114England1997–99First contactSCAN, consensus panelICD-10Non-aff, schz, oth218
Stain et al 2008115Australia2001–2005First contactCase notesOtherOth308
Boonstra et al 2008116Netherlands2002First contactClinical diagnosisDSM-4Non-aff75
Crebbin et al 2008117*England1998–2005Case registerChart diagnosisICD-10FEP, schz, pd540
Farquhar et al 200845Wales1875–2005First admissionCase recordsICD-10Schz, schza, aff, bpd, pd, oth579
Pelayo-Teran et al 200810Spain2001–05First contactSCID-IDSM-4Non-aff174
Castagnini et al 2008118*Denmark1996Case registerNoneICD-8Schz, bpd, oth11 126
Burns et al 200814South Africa2005First presentationCase recordsDSM-4FEP160
Weiser et al 2008119Israel..Population registerNoneICD-9, ICD-10Schz1686
Veling et al 2008120Netherlands1997–2005First contactDiagnostic meetingDSM-4FEP, non-aff, bpd, pd, oth466
Kirkbride et al 2008a121England1997–99First contactSCAN, consensus panelICD-10Schz148
Kirkbride et al 2008b122England1996–2000First contactSCAN, consensus panelDSM-4FEP, schz, non-aff, oth484
Coid et al 200123England1996–2000First contactSCAN, consensus panelDSM-4FEP, non-aff, schz, aff, oth484
Grant et al 200124††USA2004–05CohortNot statedDSM-4Bpd263
Crebbin et al 2009125*England1998–2005Case registerChart diagnosisICD-10Schz, sip430
Bih et al 2009126*††Taiwan1996–2003CohortNoneICD-9Bpd532
Corcoran et al 2009127Israel1964–97CohortNoneICD-10Non-aff637
Osby et al 2009128*Sweden1997–2005Case registerNoneICD-10Bpd4117
Valdimarsdottir et al 2009129Sweden1983–2000CohortNoneICD-8, ICD-9FEP4557
Harlap et al 2009130Israel1964–76CohortNoneICD-10Schz637
Reay et al 2009131England1998–2005First contactChart diagnosisICD-10FEP, non-aff, schz, aff, bpd, pd540
Norredam et al 2009132Denmark1994–2003CohortNoneICD-10Non-aff1127
Bogren et al 2009133Sweden1947–97First contactKey informants, case filesDSM-4Non-aff, schz, schza, aff, bpd61
Kirkbride et al 2009134England1978–99CombinationSCAN, consensus agreementICD-9, ICD-10FEP, non-aff, schz, aff, bpd, pd, sip, oth347
Coid et al 2009123..............
Cheng et al 2010135England2002–2007First contactUnsureICD-10FEP285
Bogren et al 201046Sweden1947–97First presentationKey informants, case filesDSM-4Non-aff, aff, bpd108
Zammit et al 2010136Sweden1972, 1977First admissionNoneICD-8, ICD-9Non-aff, schz881
Tseng et al 2010137Taiwan1996–2001First hospitalisationNoneICD-9SchzUnknown
Zandi et al 2010138Netherlands2002–04First contactCASH or CASH-CS, medical files, consensus diagnosisDSM-4FEP, schz77
Norredam et al 2010139Denmark1994–2003CohortNoneICD-10Non-aff791
Goodman et al 201147**USA..First contactNot statedICD-9FEP8
Cowan et al 2011140**USA2000–09First hospitalisationNoneICD-9Non-aff2722
Harris et al 2011141*Wales1875–2005First admissionPanel assessment of case notesICD-10Pd800
Jorgensen et al 2011142Sweden2005Case registerRandom sample checked by psychiatristICD-10Non-aff, schz416
Cheng et al 2011143England2002–07First contactMultidisciplinary diagnostic meetingICD-10FEP285
Kleinhaus et al 2011144Israel1964–76CohortNoneICD-10Non-aff860
Benros et al 2011145Denmark1945–96Population registerNoneICD-8, ICD-10Non-aff39 076
Salokangas et al 2011146Finland..Case registerNoneICD-8, DSM-3-R, ICD-10Schz30 032
Schofield et al 2011147England1996–2006First GP recordPatient recordsREAD codesFEP508
Veling et al 2011148Netherlands1997–2005First contactDiagnostic meetingDSM-4FEP618
Healy et al 2012149*Wales1875–2005First admissionCase records, clinical diagnosisICD-10Schz, oth3523
Callaghan et al 2012150*USA1990–2000First hospitalisationNot statedICD-9Schz1499
Anderson et al 2012151Canada2000–06First contactNone..Non-aff546
Manrique-Garcia et al 2012152**Sweden1969–70First admissionNoneICD-8, ICD-9Non-aff, schz674
Turola et al 2012153Italy1979–2008First diagnosisCase notesDSM-4, ICD-10Schz1759
Werbeloff et al 2012154Israel1979–92Case registerNoneICD-9Schz2335
Nosarti et al 2012155Sweden1973–85First admissionNoneICD-8 and ICD-9Non-aff, bpd886
Gigantesco et al 2012156Italy2008First contactSCID-I, BPRS, GAF in duplicateDSM-4FEP, bpd247
Tarricone et al 201211Italy2002–09First contactSCAN, consensus diagnosisICD-10FEP, Non-aff, schz, aff163
Kirkbride et al 2012157England2009–11First presentationClinical diagnosesICD-10FEP..
Hung et al 2013158††Taiwan2000–05CohortNoneICD-9Bpd9711
Peritogiannis et al 2013159Greece2008–09First contactNoneICD-10FEP132
Sutterland et al 2013160Netherlands1996–2006First GP recordMedical recordsICPCNon-aff, schz293
Cantor-Graae et al 2013161Denmark1995–2010Population registerNoneICD-8, ICD-10Non-aff, schz, schza, bpd13 729
Kroon et al 2013162Netherlands1996–2007First GP recordMedical recordsICPCBpd649
Castagnini et al 2013163Denmark1995–2008First diagnosisNoneICD-10Oth11 126
Hardoon et al 2013164England2000–10First record or diagnosisGP recordsREADSchz, bpd, oth10 520
Weibell et al 2013165Norway2007–11First presentationSCIDDSM-4Non-aff, sip321
Cocchi et al 2014166Italy2007–09First contactERIaos-CL, sociodemographic form, HoNOS, BPRS, WHO-DAS IIIICD-10Non-aff43
Tortelli et al 2014167France2005–09First admissionCase notesICD-10FEP258
Hogerzeil et al 201437Netherlands2000–05First contact and case registerDiagnostic meeting and clinical regularly audited)DSM-4Schz254; 843
Pedersen et al 2014168*Denmark1995–2006Case registerNoneICD-10OthUnknown
Sørensen et al 2014169*Denmark1993–95Population registerNoneICD-8, ICD-10Schz17 389
Munk-Olsen et al 2014170Denmark1960–95First treatmentNoneICD-8, ICD-9OthUnknown
Szoke et al 2014171France2010–12First contactIdentical procedures, regular meetingsDSM-4FEP, non-aff, aff133
Bhavsar et al 2014172England2000–07First contactCase notesRDCSchz405
Omer et al 2014173Ireland1995–2000First contactSCID or clinical recordsDSM-4FEP336
Lasalvia et al 20149Italy2005–07First contactInterview, consensus diagnosisICD-10FEP, non-aff, schz, aff, bpd, pd558
Veling et al 2014174Netherlands1997–2005First contactDiagnostic meetingDSM-4FEP, schz, aff, bpd, pd, oth618
Kirkbride et al 201434England1996–2000First contactSCAN, consensus diagnosisDSM-4Non-aff, aff484
Anderson et al 20155Canada1999–2008Population registerMedical records or billing claimsNon-affUnknown
Paksarian et al 2015a175Denmark1986–2010Population registerNoneICD-8, ICD-10Non-aff, schz, bpd15 811
Sørensen et al 2015176Denmark1955–67Population registerNoneICD-8, ICD-10Non, aff, schz, aff15 074; 7562
Paksarian et al 2015b177Denmark1986–2011Population registerNoneICD-8, ICD-10Non-aff, schz, bpd14 285
Soderlund et al 2015178Sweden1955–67Population registerNoneICD-10Non-aff, schz, aff2322
Medici et al 2015179††Denmark1995–2012Case registerNoneICD-10Bpd15 334
Carlborg et al 2015180††Sweden1991–2010Case registerNoneICD-10Bpd10 273
Tsai et al 2016181††Taiwan2000–07CohortNoneICD-9Bpd202
Chen et al 2015182††Taiwan2000–06CohortNoneICD-9-CMBpd, pd118
Latvala et al 2016183**Sweden1969–2010Case registerNoneICD-8/9/10Schz, bpd14 840
Jensen et al 2016184*††Denmark1995–2010Case registerNoneICD-10Bpd12 034
Kuhl et al 2016185*Denmark2000–12Population registerNoneICD-10Non-aff, schz23 479
Filatova et al 2016186Finland1966–2013CohortNoneICD-8, ICD-10Non-aff, schz, bpd, oth295
Chiang et al 201648Taiwan1998–2007First admissionNoneICD-9-CMFEP69 690
Nielsen et al 2016187Denmark1997–2002Population registerNoneICD-8, ICD-10Schz6927
Kendler et al 201649Sweden1972–90Population registerNoneICD-9, ICD-10Non-aff, schz, bpd22 589
Levine et al 2016a188*Israel1950–2004CohortNoneICD-10Schz2278
Levine et al 2016b189*Israel1950–2014CohortNoneICD-10Schz665
Vassos et al 201650Denmark1995–2006Population registerNoneICD-10FEP, non-aff, bpd32 983
Sørensen et al 2016190*Denmark1930–76CohortNoneICD-8, ICD-10Schz4936
Hollander et al 2016191Sweden1998–2011Population registerNoneICD-10Non-aff3704
O'Donoghue et al 2016192Ireland2006–11First presentationSCIDDSM-4FEP292
Morgan et al 201615India, Nigeria, Trinidad..First contactSSP, consensus diagnosisICD-10FEP147
Tarricone et al 2016193Italy2002–10First contactSCANICD-10FEP187
Szoke et al 2016194France2010–14First contactUnclear—senior review if uncertainDSM-4Non-aff, aff212
Mulé et al 201612Italy2008–11First contactSCANICD-10FEP, schz, aff, oth204
Ramsey et al 201751**USA2001–14CohortNoneICD-9Schz, bpd24 714
Okkels et al 2017195Denmark1985–2001Population registerNoneICD-8, ICD-10Non-aff, schz, bpd9329
Vikstrom et al 2017196Sweden1988–2012CohortNoneICD-8, ICD-10Non-aff, bpd91
Wang et al 2017197Taiwan1997–2007CohortNoneICD-9Schz238
Lin et al 2017198††Taiwan2001–06CohortNoneICD-9 CMBpd183
Marrie et al 2017a199Canada1989–2012Case registerNoneICD-9 CMSchz, bpdUnknown
Marrie et al 2017b200Canada1984–2013Case registerNoneICD-9 CMSchz, bpdUnknown
Hogerzeil et al 2017201Netherlands2000–05First contact or case registerStructured interview or clinical, then consensusDSM-4Schz254; 843
Hoeffding et al 2017202Denmark1995–2013Population registerNoneICD-8, ICD-10Non-aff31 647
Kim et al 201752South Korea2002–13CohortNoneICD-10Non-aff9387
Markkula et al 201753Finland2011–14Population registerNoneICD-10Non-aff, bpd2905
Nielsen et al 2017203Denmark1955–99Population registerNoneICD-8, ICD-10Schz21 305
Schofield et al 2017204Denmark1965–97Population registerNoneICD-8, ICD-10Non-aff26 891
Simon et al 201754USA2007–13First contactNone, subset case recordsICD-9FEP37 843
Kirkbride et al 2017a205England2009–13First contactOPCRITICD-10FEP, non-aff, schz, aff, bpd, pd, sip687
Kirkbride et al 2017b206England2009–13First contactOPCRITICD-10FEP, non-aff, schz, aff687
Schofield et al 2018207Denmark1965–2013Population registerNoneICD-8, ICD-10Non-affUnknown
Nyberg et al 2018208**‡‡Sweden1968–2005CohortNoneICD-8, ICD-9, ICD-10Non-aff4641
Barghadouch et al 2018209‡‡Denmark1993–2000CohortNoneICD-10Non-aff392
Richardson et al 2018210‡‡England2009–13First contactOPCRITICD-10FEP, non-aff, schz, aff0687
Jongsma et al 201855England, Netherlands, France, Spain, Italy, Brazil2005–15First contactSCAN, CASH, DIGS, SID, or case notes—OPCRITICD-10FEP, non-aff, aff2774

All references up to and including 60 are found in the reference list of the main article. References from 61 onwards are found in the appendix (pp 35–43). Aff=affective psychosis. Bpd=bipolar disorder. BPRS=Brief Psychiatric Rating Scale. CASH=Comprehensive Assessment of Symptoms and History. CASH-CS=CASH-Culturally Sensitive. DIGS=Diagnostic Interview for Genetic Studies. DSM=Diagnostic and Statistical Manual. ERIaos-CL=Early Recognition Inventory Retrospective Assessment of Symptoms checklist. FEP=all first episode psychosis. GAF=Global Assessment of Functioning. HoNOS=Health of the Nations Outcome Scale. ICD=International Classification of Disease. Non-aff=non-affective psychosis. OCCPI=Operational Criteria Checklist for Psychotic Illness. OPCRIT=Operational Criteria Checklist for Psychotic Illness. Oth=other. Pd=psychotic depression. PPHS=Personal and Psychiatric History Schedule. PSE=Present State Examination. RDC=Research Diagnostic Criteria. RPMIP=Royal Park Multidiagnostic Instrument for Psychosis. SANS=Scale for the Assessment of Negative Symptoms. SCAN=Schedules Clinical Assessment Neuropsychiatry. Schz=schizophrenia. Schzp=schizophreniform disorder. Schza=schizoaffective disorder. SCID=Structural Clinical Interview for DSM-4. SCID-I=SCID-Axis I disorders. Sip=substance-induced psychosis. SID=Structured Interview for DSM-4. SSP=Screening Schedule for Psychosis. WHO-DAS III=WHO Disability Assessment Schedule.

Citations with insufficient data to include in quantitative analyses.

Citations only covering young people (<40 years).

Citations only containing information covered in more detail in other citations.

Citations covering a prison population.

Citations covering post-partum psychosis.

Citations covering comorbid populations.

Citations covering the army only.

Citations including psychotic bipolar disorder, but where this can't be clearly differentiated from bipolar disorder more widely (not included in analyses).

Published online in 2017.

PRISMA flowchart *Citations derived from Kirkbride and colleagues, which cover England only from 2002–09. Study characteristics of included citations All references up to and including 60 are found in the reference list of the main article. References from 61 onwards are found in the appendix (pp 35–43). Aff=affective psychosis. Bpd=bipolar disorder. BPRS=Brief Psychiatric Rating Scale. CASH=Comprehensive Assessment of Symptoms and History. CASH-CS=CASH-Culturally Sensitive. DIGS=Diagnostic Interview for Genetic Studies. DSM=Diagnostic and Statistical Manual. ERIaos-CL=Early Recognition Inventory Retrospective Assessment of Symptoms checklist. FEP=all first episode psychosis. GAF=Global Assessment of Functioning. HoNOS=Health of the Nations Outcome Scale. ICD=International Classification of Disease. Non-aff=non-affective psychosis. OCCPI=Operational Criteria Checklist for Psychotic Illness. OPCRIT=Operational Criteria Checklist for Psychotic Illness. Oth=other. Pd=psychotic depression. PPHS=Personal and Psychiatric History Schedule. PSE=Present State Examination. RDC=Research Diagnostic Criteria. RPMIP=Royal Park Multidiagnostic Instrument for Psychosis. SANS=Scale for the Assessment of Negative Symptoms. SCAN=Schedules Clinical Assessment Neuropsychiatry. Schz=schizophrenia. Schzp=schizophreniform disorder. Schza=schizoaffective disorder. SCID=Structural Clinical Interview for DSM-4. SCID-I=SCID-Axis I disorders. Sip=substance-induced psychosis. SID=Structured Interview for DSM-4. SSP=Screening Schedule for Psychosis. WHO-DAS III=WHO Disability Assessment Schedule. Citations with insufficient data to include in quantitative analyses. Citations only covering young people (<40 years). Citations only containing information covered in more detail in other citations. Citations covering a prison population. Citations covering post-partum psychosis. Citations covering comorbid populations. Citations covering the army only. Citations including psychotic bipolar disorder, but where this can't be clearly differentiated from bipolar disorder more widely (not included in analyses). Published online in 2017. The largest study in this Article included 69 690 cases, and the smallest study identified eight cases. The middle year of recruitment varied from 1908 to 2012, with most citations (105 [59%]) recruiting between approximately 1995 and 2006. Most studies reported a clearly defined catchment area (174 [98%]), clearly listed their inclusion criteria (166 [94%]), used accurate denominator data (157 [89%]), and employed population-based case-finding (135 [76%]). Few studies done used a standardised research diagnosis (50 [28%]), did a leakage study (28·5 [16%]), or used blinding to demographic variables (18 [10%]; appendix pp 6–8). 92 (52%) citations reflected first contact designs and 76 (43%) used a cohort, case, or population register. The remaining nine (5%) studies used a combination. 40 (23%) citations used a version of the DSM for diagnoses and 118 (67%) used a version of ICD. The remaining 19 (11%) used a combination, used a different diagnostic system, such as the Research Diagnostic Criteria, or it was not reported (three [2%]; table). To confirm clinical diagnoses, 21 (12%) citations used a structured interview instrument only, 19 (11%) reviewed medical records, 14 (8%) used a structured interview followed by consensus diagnosis, 13 (7%) used only an interview without specifying whether an instrument was used, ten (6%) used only a consensus or panel discussion, and five (2%) used a chart or clinical diagnoses. The remaining citations either relied solely on clinical diagnoses in registry data (85 [48%]), or information was not stated (ten [6%]; table). We included 44 separate estimates of the incidence of all psychotic disorders derived from 27 citations, including estimates from multicentre studies (figure 2). Incidence varied around 15 times, from 6·3 per 100 000 person-years (95% CI 4·5–8·8) in Santiago (Spain) to 90·0 (88·3–91·8) in the USA. The overall pooled incidence of all psychotic disorders was 26·6 per 100 000 person-years (22·0–31·7).
Figure 2

Incidence of all psychotic disorders

References from 61 onwards are found in the appendix (pp 35–43). IR=incidence rates. Note: weights are from random effects analysis.

Incidence of all psychotic disorders References from 61 onwards are found in the appendix (pp 35–43). IR=incidence rates. Note: weights are from random effects analysis. Incidence of non-affective disorders was available from 47 incidences derived from 28 citations (figure 3). Incidence varied almost 30 times, from 5·2 per 100 000 years (95% CI 3·7–7·4) in Santiago to 148·4 (142·7–154·4) in Finland. The overall pooled incidence was 18·7 per 100 000 person-years (14·8–23·6), but this incidence was lower in first-contact studies at 17·4 (14·6–20·8) compared with population register studies (pooled incidence rate 90·9 [34·5–237·5]; figure 3). The incidence of schizophrenia was available from 36 incidences from 26 citations and varied from 2·7 per 100 000 person-years (1·4–5·3) in Cavan-Monaghan (Ireland) to 75·9 (74·4–77·5) in South Korea. Pooled incidence was lower in first contact studies (13·1 per 100 000 person-years [9·0–15·0]) than in population registers (32·8 [23·2–46·5]; figure 4).
Figure 3

Incidence of non-affective disorders

References from 61 onwards are found in the appendix (pp 35–43). IR=incidence rates. Note: weights are from random effects analysis.

Figure 4

Incidence of schizophrenia

References from 61 onwards are found in the appendix (pp 35–43). IR=incidence rates. Note: weights are from random effects analysis.

Incidence of non-affective disorders References from 61 onwards are found in the appendix (pp 35–43). IR=incidence rates. Note: weights are from random effects analysis. Incidence of schizophrenia References from 61 onwards are found in the appendix (pp 35–43). IR=incidence rates. Note: weights are from random effects analysis. We pooled 34 estimates of the incidence of affective psychotic disorders from 16 citations. Incidence varied from 0·9 per 100 000 person-years (95% CI 0·4–2·2) in Santiago to 17·0 (10·8–26·6) in Lundby (Sweden). The overall pooled rate was 4·6 per 100 000 person-years (3·1–6·8; figure 5). 24 estimates of the incidence of bipolar disorder were included in a meta-analysis, derived from 15 citations. Incidence varied from 1·4 per 100 000 person-years (1·0–2·0) in Wales to 28·5 (28·0–29·1) in Sweden, and was higher in population registers (15·1 [10·2–22·3]) than first contact studies (3·6 [2·0–6·5]; figure 6). Insufficient citations were available to pool rates for other outcomes.
Figure 5

Incidence of affective disorders

References from 61 onwards are found in the appendix (pp 35–43). IR=incidence rates. Note: weights are from random effects analysis.

Figure 6

Incidence of bipolar disorder

References from 61 onwards are found in the appendix (pp 35–43). IR=incidence rates. Note: weights are from random effects analysis.

Incidence of affective disorders References from 61 onwards are found in the appendix (pp 35–43). IR=incidence rates. Note: weights are from random effects analysis. Incidence of bipolar disorder References from 61 onwards are found in the appendix (pp 35–43). IR=incidence rates. Note: weights are from random effects analysis. Pooled estimates of the incidence of all psychotic disorders were similar across high-income and LMICs (appendix pp 11–16), though heterogeneity was substantial in both sets of data; formal comparisons were hampered by insufficient studies in LMICs. For all psychotic disorders, 26 estimates of IRRs in men compared with women were available from 10 citations, with a pooled IRR of 1·44 (95% CI 1·27–1·62). A similar pattern was observed for non-affective psychoses (1·60 [1·44–1·77]; derived from 27 estimates using 11 citations) and schizophrenia (1·70 [1·46–1·97]; derived from 11 estimates using 11 citations). No excess risk in men was found for affective disorders (IRR 0·87 [0·75–1·00]; p=0·07; derived from 20 estimates using six citations) or for psychotic bipolar disorder (0·90 [0·73–1·11]; derived from five estimates; appendix p 17). Insufficient citations were available to pool IRRs for other outcomes. Migrants and their descendants were at excess risk of all psychotic disorders, non-affective disorders, and schizophrenia (insufficient citations were available to synthesise results for other diagnostic outcomes). When pooling all migrant groups to a binary majority or minority division, 22 estimates from seven citations were available to pool IRRs for all psychotic disorders (pooled IRR 1·75 [95% CI 1·53–2·00]). The pooled IRR for non-affective disorders was 1·71 (1·40–2·09), derived using 28 estimates from thirteen citations. The pooled IRR for schizophrenia was 1·41 (1·15–1·75), derived using six estimates (appendix p 18). Risk was not equitably distributed across ethnic minority groups (appendix pp 19–21). We did not pool estimates by age group because of the large variety of age groups used. Nonetheless, we observed an overall pattern of higher incidence in younger age groups (appendix pp 22–24). For example, in the multinational EU-GEI study incidence of all first episode psychosis ranged from 44·2 per 100 000 person-years (95% CI 42·2–46·2) in people aged 18–24 years to 5·5 (3·2–7·7) in people aged 60–64 years. We found some evidence that study design was associated with variation in incidence. Population registers had higher incidences of non-affective disorders (IRR 9·64 [2·72–31·82]), schizophrenia (2·54 [1·24–5·21]), and bipolar disorder (4·53 [2·41–8·51]) than first contact studies. Incidence of schizophrenia was also elevated in cohort studies (3·10 [1·12–8·53]) and case registers (3·12 [1·33–7·29]). Cohort studies (0·43 [0·20–0·93]) and population registers (0·42 [0·22–0·83]) recorded lower IRRs by minority status for non-affective disorders than first contact designs, but we found no differences by study design in IRRs for any other exposure or outcome association. We found little evidence that study quality and time period were associated with changes in incidence or IRR (appendix pp 25–28). Heterogeneity was high across study outcomes (I2 ≥98·5%; Figure 2, Figure 3, Figure 4, Figure 5, Figure 6). Small study effects, as evidenced by Egger's test, were shown in the overall meta-analyses of incidences of all psychotic disorders (β −7·53 [SE 3·14]; p=0·021), non-affective disorders (–14·55 [2·46]; p<0·001), schizophrenia (–11·78 [5·52]; p=0·041), affective disorders (7·72 [1·60]; p<0·001), and bipolar disorder (–14·97 [2·78]; p<0·001). They were also found in analyses by sex for all psychotic disorders (2·16 [0·44]; p<0·001) and affective disorders (0·90 [0·24]; p=0·001), but not for other diagnostic outcomes or for analyses by ethnic group (appendix pp 29–32). Post-hoc sensitivity analyses supported some remaining small study effects within first contact designs (appendix p 32).

Discussion

Our systematic review identified 177 citations containing data on the incidence of psychotic disorders published since 2002. This yield is considerably higher than reported in another systematic review and was marked by substantial heterogeneity in incidence across all major psychotic disorders. Although we found no evidence that incidences varied with study quality or time period, we did observe strong evidence of higher incidence rates reported in register-based or cohort-based study designs than in first-contact studies. Given that register-based or cohort-based studies are often done with whole population samples (ie, the USA,51, 54 Sweden, Denmark, Taiwan), this difference was consistent with our evidence of small study effects, whereby smaller studies tended to estimate lower incidence rates. Together with the high levels of statistical heterogeneity observed in our meta-analyses, our results suggest that methodological variation might partially obscure true heterogeneity in the incidence of psychotic disorders. Nonetheless, as previously established, we found strong evidence of higher incidences of all first episode psychosis and non-affective psychotic disorders in men and ethnic minority groups, with less evidence of such differences for affective psychotic disorders. The strength of our study is that our search strategy was inclusive and based on a previously used strategy with good reliability. We searched multiple databases without restriction by place or language of publication. Although individual studies might have been missed, given the size of our yield we consider it unlikely that these missing data would have substantially altered our main conclusions. One limitation of our Article was that some citations provided incidence estimates from multiple catchment areas (notably Jongsma and colleagues, 2018), which we included as separate estimates in meta-analyses. We acknowledge this inclusion might have conservatively biased SEs around effect sizes. Nonetheless, it would not have affected our observation of substantial interestimate heterogeneity in incidence, which was the primary focus of our Article. Future studies should consider adopting individual-participant data approaches, which account for clustering by design. We used a previously published, clinician-informed algorithm to group estimates into major psychotic disorder categories. However, for non-affective disorders particularly, the use of this algorithm led to the categorisation of studies that used several overlapping diagnostic outcomes (appendix pp 33–34), which might have contributed to heterogeneity. Although our quality assessment tool was based on epidemiological good practice, we acknowledge it might have been skewed towards first-contact studies given it is not feasible to assess some criteria (ie, blinding) in register-based designs. Despite this, our quality assessment aided in assessing the gaps in the published literature. The most recent systematic review and meta-analysis of all psychotic disorders identified substantially fewer citations (N=33) than our Article and provided no assessment or investigation of heterogeneity, despite similar inclusion criteria and time frames. The estimates of our more comprehensive review are aligned: we found a pooled estimate of non-affective disorders of 18·7 per 100 000 person-years (95% CI 14·8–23·7) and of affective disorders of 4·8 (3·3–6·9) compared with their estimates of 22·5 (16·5–28·5) for non-affective and 7·1 (1·4–12·2) for affective disorders. Our findings on the excess of psychoses in men were nuanced: the overall excess found in both reviews appears to be primarily driven by an excess in non-affective disorders in line with other meta-analytic evidence.27, 28 The median incidence of schizophrenia in our Article (21·7 per 100 000 person-years [IQR 5·6–52·0]) was higher than in the last major systematic review on this topic by McGrath and colleagues (15·2 [7·7–43·0]), with greater variation around these estimates. The only systematic review pertaining to mood disorders solely synthesised incidence of major depressive disorder and as such is not directly comparable to the present Article. The excess risk of (non-affective) psychotic disorders in migrants and their descendants is long-established, well-reported,20, 29 and covered elaborately in one publication. The present Article presents a varied epidemiological landscape, which partly appears to reflect methodological differences in study design. We found substantial heterogeneity both within and between study designs, with incidences of non-affective disorders, schizophrenia, and bipolar disorder higher in registry-based studies than in first contact studies. Different study designs were more common for different outcomes; for instance, a large proportion of schizophrenia studies were population registers, potentially contributing to this pooled estimate being higher than the pooled estimate of non-affective disorders (a broader category). Although individual studies36, 37 have done direct comparisons between different study designs, to our knowledge this study is the first systematic review to have investigated such differences. From a public mental health perspective, our results highlight the importance of parsing out potentially causally-relevant signals in geographical variance in incidence from noise generated through varying study designs used in different settings; individual studies16, 55, 59 that have done so suggest substantive variation in the global burden of psychotic disorders remains. Nevertheless, more research is required to understand heterogeneity in incidence produced by different study designs. One possible explanation is that register-based studies primarily (though not exclusively) originate from Scandinavian countries, and higher incidences might indicate an association between latitude and psychotic disorders (which is well-reported, but poorly understood). Alternatively, although registry-based studies might ascertain new cases of psychotic disorder across an entire (usually secondary and tertiary) health-care system, not limited to contact with mental health providers, they also rely heavily on diagnoses made in clinical practice. Although such diagnoses are reliable, first-contact studies are often able to include standardised diagnostic assessments, which might reduce the number of false positives, leading to lower reported incidence. Small study effects are not necessarily due to publication bias and in our Article are consistent with the possibility of lower incidence rates reported in first contact designs; registry-based or insurance database-based studies tended to include a larger number of cases (table). However, sensitivity analyses (appendix p 32) suggest some within-type small study effects remained, which might reflect real variance between for instance urban (where a large number of cases accrue) and rural areas. In this Article, we were unable to assess effects of urbanicity, latitude, or other socioeconomic variables due to the preponderance of country-wide estimates for which no meaningful values could be assigned. The geographical spread of studies in this Article remained mostly limited to Europe, Northern America, or Australia. One public health implication of our findings is the continued dearth of evidence outside of these settings, which might have profound consequences; for example, a cross-sectional study suggested the well established link between urbanicity and psychosis might not apply in LMICs. To fully understand and provide effective public mental health responses to the global burden of psychotic disorders, we will require methodologically-rigorous and culturally-appropriate epidemiological studies to delineate the incidence of psychotic disorders in a broader range of settings than has thus far been considered. Finally, our findings also suggest that developing international guidelines for investigation of the incidence of psychotic disorders in different settings could help minimise methodological heterogeneity in the reporting of psychosis incidence across the globe.
  54 in total

1.  Mental illness and social conditions in Bristol.

Authors:  E H HARE
Journal:  J Ment Sci       Date:  1956-04

2.  Incidence of schizophrenia or other psychoses in first- and second-generation immigrants: a national cohort study.

Authors:  Teresa Saraiva Leão; Jan Sundquist; Golin Frank; Leena-Maria Johansson; Sven-Erik Johansson; Kristina Sundquist
Journal:  J Nerv Ment Dis       Date:  2006-01       Impact factor: 2.254

3.  Epidemiology of first-episode psychosis: illustrating the challenges across diagnostic boundaries through the Cavan-Monaghan study at 8 years.

Authors:  Patrizia Baldwin; David Browne; Paul J Scully; John F Quinn; Maria G Morgan; Anthony Kinsella; John M Owens; Vincent Russell; Eadbhard O'Callaghan; John L Waddington
Journal:  Schizophr Bull       Date:  2005-06-08       Impact factor: 9.306

Review 4.  Schizophrenia and migration: a meta-analysis and review.

Authors:  Elizabeth Cantor-Graae; Jean-Paul Selten
Journal:  Am J Psychiatry       Date:  2005-01       Impact factor: 18.112

5.  The global costs of schizophrenia.

Authors:  Martin Knapp; Roshni Mangalore; Judit Simon
Journal:  Schizophr Bull       Date:  2004       Impact factor: 9.306

Review 6.  Prevalence and incidence studies of mood disorders: a systematic review of the literature.

Authors:  Paul Waraich; Elliot M Goldner; Julian M Somers; Lorena Hsu
Journal:  Can J Psychiatry       Date:  2004-02       Impact factor: 4.356

7.  Young cases of schizophrenia identified in a national inpatient register--are the diagnoses valid?

Authors:  Ch Dalman; J Broms; J Cullberg; P Allebeck
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2002-11       Impact factor: 4.328

8.  Sex differences in the risk of schizophrenia: evidence from meta-analysis.

Authors:  Andre Aleman; René S Kahn; Jean-Paul Selten
Journal:  Arch Gen Psychiatry       Date:  2003-06

9.  Heterogeneity in incidence rates of schizophrenia and other psychotic syndromes: findings from the 3-center AeSOP study.

Authors:  James B Kirkbride; Paul Fearon; Craig Morgan; Paola Dazzan; Kevin Morgan; Jane Tarrant; Tuhina Lloyd; John Holloway; Gerard Hutchinson; Julian P Leff; Rosemarie M Mallett; Glynn L Harrison; Robin M Murray; Peter B Jones
Journal:  Arch Gen Psychiatry       Date:  2006-03

Review 10.  A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology.

Authors:  John McGrath; Sukanta Saha; Joy Welham; Ossama El Saadi; Clare MacCauley; David Chant
Journal:  BMC Med       Date:  2004-04-28       Impact factor: 8.775

View more
  42 in total

1.  Migration, ethnicity and psychoses: evidence, models and future directions.

Authors:  Craig Morgan; Gemma Knowles; Gerard Hutchinson
Journal:  World Psychiatry       Date:  2019-10       Impact factor: 49.548

2.  Universal healthcare coverage for first episode of schizophrenia-spectrum disorders in Chile: analysis of the administrative database.

Authors:  Verónica Larach; Luis F Varela; Guillermo Vergara; Irma Rojas; Viviana Hernández; Rodrigo Casanueva; Matías Irarrázaval
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2021-03-26       Impact factor: 5.270

3.  Prognostic accuracy and clinical utility of psychometric instruments for individuals at clinical high-risk of psychosis: a systematic review and meta-analysis.

Authors:  Dominic Oliver; Maite Arribas; Joaquim Radua; Gonzalo Salazar de Pablo; Andrea De Micheli; Giulia Spada; Martina Maria Mensi; Magdalena Kotlicka-Antczak; Renato Borgatti; Marco Solmi; Jae Il Shin; Scott W Woods; Jean Addington; Philip McGuire; Paolo Fusar-Poli
Journal:  Mol Psychiatry       Date:  2022-06-03       Impact factor: 15.992

4.  Structural Racism and Inequities in Incidence, Course of Illness, and Treatment of Psychotic Disorders Among Black Americans.

Authors:  Supriya Misra; Onisha S Etkins; Lawrence H Yang; David R Williams
Journal:  Am J Public Health       Date:  2022-04       Impact factor: 9.308

Review 5.  Sex Differences in the Gut-Brain Axis: Implications for Mental Health.

Authors:  Calliope Holingue; Alexa Curhan Budavari; Katrina M Rodriguez; Corina R Zisman; Grace Windheim; M Daniele Fallin
Journal:  Curr Psychiatry Rep       Date:  2020-11-20       Impact factor: 5.285

6.  Association of preceding psychosis risk states and non-psychotic mental disorders with incidence of clinical psychosis in the general population: a prospective study in the NEMESIS-2 cohort.

Authors:  Sinan Guloksuz; Lotta-Katrin Pries; Margreet Ten Have; Ron de Graaf; Saskia van Dorsselaer; Boris Klingenberg; Maarten Bak; Bochao D Lin; Kristel R van Eijk; Philippe Delespaul; Therese van Amelsvoort; Jurjen J Luykx; Bart P F Rutten; Jim van Os
Journal:  World Psychiatry       Date:  2020-06       Impact factor: 49.548

7.  Impact of humanized nursing care on negative emotions and quality of life of patients with mental disorders.

Authors:  Liping Bao; Congcong Shi; Jing Lai; Yan Zhan
Journal:  Am J Transl Res       Date:  2021-11-15       Impact factor: 4.060

8.  The incidence of psychotic disorders among migrants and minority ethnic groups in Europe: findings from the multinational EU-GEI study.

Authors:  Fabian Termorshuizen; Els van der Ven; Ilaria Tarricone; Hannah E Jongsma; Charlotte Gayer-Anderson; Antonio Lasalvia; Sarah Tosato; Diego Quattrone; Caterina La Cascia; Andrei Szöke; Domenico Berardi; Pierre-Michel Llorca; Lieuwe de Haan; Eva Velthorst; Miguel Bernardo; Julio Sanjuán; Manuel Arrojo; Robin M Murray; Bart P Rutten; Peter B Jones; Jim van Os; James B Kirkbride; Craig Morgan; Jean-Paul Selten
Journal:  Psychol Med       Date:  2020-09-22       Impact factor: 10.592

9.  Informal carers in severe mental health conditions: Issues raised by the United Kingdom SARS-CoV-2 (COVID-19) Pandemic.

Authors:  Juliana Onwumere
Journal:  Int J Soc Psychiatry       Date:  2020-05-10

10.  Sex-Dependent Shared and Nonshared Genetic Architecture Across Mood and Psychotic Disorders.

Authors:  Gabriëlla A M Blokland; Jakob Grove; Chia-Yen Chen; Chris Cotsapas; Stuart Tobet; Robert Handa; David St Clair; Todd Lencz; Bryan J Mowry; Sathish Periyasamy; Murray J Cairns; Paul A Tooney; Jing Qin Wu; Brian Kelly; George Kirov; Patrick F Sullivan; Aiden Corvin; Brien P Riley; Tõnu Esko; Lili Milani; Erik G Jönsson; Aarno Palotie; Hannelore Ehrenreich; Martin Begemann; Agnes Steixner-Kumar; Pak C Sham; Nakao Iwata; Daniel R Weinberger; Pablo V Gejman; Alan R Sanders; Joseph D Buxbaum; Dan Rujescu; Ina Giegling; Bettina Konte; Annette M Hartmann; Elvira Bramon; Robin M Murray; Michele T Pato; Jimmy Lee; Ingrid Melle; Espen Molden; Roel A Ophoff; Andrew McQuillin; Nicholas J Bass; Rolf Adolfsson; Anil K Malhotra; Nicholas G Martin; Janice M Fullerton; Philip B Mitchell; Peter R Schofield; Andreas J Forstner; Franziska Degenhardt; Sabrina Schaupp; Ashley L Comes; Manolis Kogevinas; José Guzman-Parra; Andreas Reif; Fabian Streit; Lea Sirignano; Sven Cichon; Maria Grigoroiu-Serbanescu; Joanna Hauser; Jolanta Lissowska; Fermin Mayoral; Bertram Müller-Myhsok; Beata Świątkowska; Thomas G Schulze; Markus M Nöthen; Marcella Rietschel; John Kelsoe; Marion Leboyer; Stéphane Jamain; Bruno Etain; Frank Bellivier; John B Vincent; Martin Alda; Claire O'Donovan; Pablo Cervantes; Joanna M Biernacka; Mark Frye; Susan L McElroy; Laura J Scott; Eli A Stahl; Mikael Landén; Marian L Hamshere; Olav B Smeland; Srdjan Djurovic; Arne E Vaaler; Ole A Andreassen; Bernhard T Baune; Tracy Air; Martin Preisig; Rudolf Uher; Douglas F Levinson; Myrna M Weissman; James B Potash; Jianxin Shi; James A Knowles; Roy H Perlis; Susanne Lucae; Dorret I Boomsma; Brenda W J H Penninx; Jouke-Jan Hottenga; Eco J C de Geus; Gonneke Willemsen; Yuri Milaneschi; Henning Tiemeier; Hans J Grabe; Alexander Teumer; Sandra Van der Auwera; Uwe Völker; Steven P Hamilton; Patrik K E Magnusson; Alexander Viktorin; Divya Mehta; Niamh Mullins; Mark J Adams; Gerome Breen; Andrew M McIntosh; Cathryn M Lewis; David M Hougaard; Merete Nordentoft; Ole Mors; Preben B Mortensen; Thomas Werge; Thomas D Als; Anders D Børglum; Tracey L Petryshen; Jordan W Smoller; Jill M Goldstein
Journal:  Biol Psychiatry       Date:  2021-03-23       Impact factor: 12.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.